These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
Pipeline and key clinical candidates for these companies:
CymaBay Therapeutics is focused on liver and other chronic diseases that have high unmet medical need. The company has received breakthrough therapy designation from the FDA, PRIority MEdicines status from the European Medicines Agency and orphan drug status in the U.S. and Europe for seladelpar, a first-in-class treatment for people with primary biliary cholangitis, or PBC.
Seelos Therapeutics is focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system, or CNS, disorders and other rare diseases. The company's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder, amyotrophic lateral sclerosis, or ALS, and spinocerebellar ataxia, or SCA, as well as early-stage programs in Huntington's disease, Alzheimer's disease, and Parkinson's disease.
Rigel Pharmaceuticals is dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases. Rezlidhia is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia, or AML, with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
vTv Therapeutics is focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease, renal disease, primary mitochondrial myopathy, and pancreatic cancer.
BioXcel Therapeutics is utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. The company’s drug re-innovation approach "leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices," BioXcel states. The company’s commercial product, IGALMI, developed as BXCL501, is a proprietary, sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Recent news on these stocks:
December 2
Citi analyst Yigal Nochomovitz upgraded Rigel Pharmaceuticals to Buy from Neutral with a price target of $2, up from $1.50. The Rezlidhia approval for relapsed or refractory acute myeloid leukemia comes 2.5 months ahead of schedule, Nochomovitz told investors in a research note. Based on key opinion leader feedback, the analyst expects Rezlidhia will eventually become the market share leader over Tibsovo. Nochomovitz raised Rezlidhia's peak share estimate from 40% to 55% by 2030.
December 1
Goldman Sachs analyst Corinne Jenkins upgraded BioXcel Therapeutics to Neutral from Sell with a $16 price target. The analyst said the stock's valuation now more accurately reflects the underlying business. She sees more limited downside to revenue estimates over the next year, "which should be supportive of shares over the early launch period," Jenkins tells investors in a research note. Moreover, the analyst expects commercial execution to be secondary to the clinical catalyst path over the course of 2023, and she sees a high likelihood of clinical success for each of BioXcel's three Phase 3 read-outs expected next year.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 15-plus million retail and financial professional investors through InvestingChannel's online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Acquired by GILD
+0.045 (+1.10%)
Seelos Therapeutics
-0.045 (-4.21%)
Rigel Pharmaceuticals
+
vTv Therapeutics
+
BioXcel Therapeutics
-0.23 (-1.27%)